Includes patients

Ulcerative Colitis (TL1A Study)

Location: Solmed Polyclinic (Zagreb)

Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.

Main Inclusion Criteria: Patients aged 18 and older with an official diagnosis of ulcerative colitis who, with at least one previous line of treatment (either conventional or biological therapy), have symptoms of active disease.

Status: Enrolling new patients soon

Start of patient enrollment: July 2024.

Planned completion of patient enrollment: May 2026.

Testimonials from
our patients

Newsletter

Receive regular notifications about our activities and news in treatments.

Free examinations